PERNIX THERAPEUTICS
Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products primarily for the pediatric market. The Company’s pediatric products, designed to improve the health and well-being of children, are focused in the specific areas of allergy, upper respiratory, including nasal, chest congestion and cough, antibiotics and dermatology, including head lice, and contact dermatitis. The Company prom... otes its products through a sales and marketing organization with approximately 55 sales representatives, primarily in highly populated states, targeting pediatric and high-prescribing physicians that are in the top decile of physicians that prescribe its products. The Company’s current operating plan focuses on maximizing sales of its existing product portfolio. In addition, Pernix plans to accelerate growth by launching new products, line extensions, and new formulations and by acquiring and licensing approved products.
PERNIX THERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1997-01-01
Address:
Houston, Texas, United States
Country:
United States
Website Url:
http://www.curraxpharma.com
Total Employee:
251+
Status:
Active
Contact:
800-793-2145
Total Funding:
99 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Domain Not Resolving Microsoft Exchange Online Office 365 Mail IPv6 GoDaddy DNS Google Google Cloud
Current Advisors List
Board_member
Board_member
Current Employees Featured
Steve A. Elms Director @ Pernix Therapeutics
Director
Michael Venters Vice President of Corporate Development @ Pernix Therapeutics
Vice President of Corporate Development
Doug Drysdale CEO, Chairman & Board of Directors @ Pernix Therapeutics
CEO, Chairman & Board of Directors
2014-02-05
George Hampton CEO @ Pernix Therapeutics
CEO
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2013-03-06 | Somaxon Pharmaceuticals | Somaxon Pharmaceuticals acquired by Pernix Therapeutics | 25 M USD |
| 2012-11-14 | Cypress Pharmaceutical | Cypress Pharmaceutical acquired by Pernix Therapeutics | 91 M USD |
Investors List
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Debt - Pernix Therapeutics
Official Site Inspections
http://www.curraxpharma.com
- Host name: 104.26.10.236
- IP address: 104.26.10.236
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
